Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 24 of 28.
Apr 2010
26 Apr · Business
Press release dated April 26, 2010, titled "Glenmark Generics receives USFDA approval for Norethindrone tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Disclosure
At the meeting of the Operations Committee of directors held on April 22, 2010 the Board has approved the conversion of 20,400 stock options issued to its employees into 20,400 Equity Shares pursuant to the ESOS 2003.12 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 12, 2010, titled "Glenmark Generics announces the settlement of Paragraph IV litigation with GSK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 07, 2010, titled "Glenmark Generics receives UK-MA approval for Ropinirole film-coated tablets and to distribute Lercanidipine Hydrochloride film-coated tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2010, titled "Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
31 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 31, 2010, titled "Glenmark Generics announced New Drug Applications for Oxycodone Hydrochloride Capsules and Liquid Solution". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 26, 2010, titled "Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.22 Mar · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on March 22, 2010 allotted 6,100 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.18 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 18, 2010, titled " Glenmark Generics receives approval from the USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Issue of Stock Options
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the Compensation Committee Meeting held on February 25, 2010 the Committee has issued 95,000 stock options @ Rs. 247.40 to the permanent employees pursuant to ESOS 2003.2 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release vide its letter dated March 02, 2010, titled " Glenmark Generics receives approval from the USFDA for Ropinirole Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
22 Feb · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Operations Committee Meeting held on February 18, 2010 allotted 70,400 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003".2 Feb · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Mr. M. Gopal Krishnan, Director; has resigned from the Board of Company with effect from January 29, 2010
Jan 2010
29 Jan · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the Compensation Committee held on January 29, 2010 the Committee has cancelled 377,100 Stock options issued to the permanent employees pursuant to ESOS 2003.29 Jan · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on January 29, 2010 allotted 59,200 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.29 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 27691.66 lacs for quarter ending on 31-DEC-2009 against Rs. 24430.62 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 3748.51 lacs for the quarter ending on 31-DEC-2009 against Rs. 3691.96 lacs for the quarter ending on 31-DEC-2008.29 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 64168.46 lacs for quarter ending on 31-DEC-2009 against Rs. 58138.94 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 9407.36 lacs for the quarter ending on 31-DEC-2009 against Rs. 8143.19 lacs for the quarter ending on 31-DEC-2008.29 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 29, 2010, titled "Glenmark's consolidated revenue increases by 10% to Rs. 6416.85 Mn for Q3-FY'10. Consolidated Net Profit increases by 15.5% at Rs.940.73 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the Third quarter of the Financial Year 2009-10 ended December 31, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 22, 2010, titled "Glenmark Generics Ltd granted tentative approval by US-FDA for Trandolapril and Verapamil Hydrochloride extended-release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Board meeting
To consider and approve the Un-Audited Financial Results for the Third Quarter ended December 31, 2009.
Dec 2009
24 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 24, 2009, titled "Glenmark Generics Ltd receives Tentative Approval from USFDA for Pramipexole Dihydrochloride tablets and Atomoxetine Hydrochloride capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 16, 2009, titled "Glenmark in-licenses its first product from Stratpharma AG, Switzerland for scar management therapy in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
26 Nov · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Operations Committee Meeting held on November 26, 2009 allotted 27500 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 16, 2009, titled "Glenmark Pharmaceuticals outlicenses a specialty pharmaceutical product to medicis pharmaceutical for the North America Region". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 16, 2009, titled "Glenmark Generics announces the settlement of Para IV litigations with Medicis Pharmaceutical Corporation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 14, 2009, titled "Glenmark Generics receives ANDA approval from US-FDA for Ciclopirox Olamine Cream". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
29 Oct · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated October 29, 2009 that "At the board meeting held today, Mr. Hocine Sidi Said, has been appointed as Additional Director of the Company. Mr. Hocine Sidi Said is the Founder & Director of Bio-nAbler, an investment company that partners with Sovereign Wealth Funds and Private Equity Firms across Asia and the MENA region to identify and execute product and company acquisitions. Mr. Said has over 20 years of experience in the pharmaceutical industry and has worked with companies like Pfizer and UCB. During his stint at UCB, he was incharge of the entire Emerging Markets Region and designated as Senior Vice President".29 Oct · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated October 29, 2009 that "At the meeting of the Board of Directors held today, the Board has approved the conversion of 64,100 stock options issued to its employees into 64,100 Equity Shares pursuant to the ESOS 2003".29 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 29, 2009, titled "Glenmark's consolidated revenue increases by 5% to Rs. 5903.26 Mn for Q2-FY'10. Consolidated Net Profit at Rs. 808.85 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the second quarter of the Financial Year 2009-10 ended September 30, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 23583.48 lacs for quarter ending on 30-SEP-2009 against Rs. 22585.42 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 5750.18 lacs for the quarter ending on 30-SEP-2009 against Rs. 6688.67 lacs for the quarter ending on 30-SEP-2008.29 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 59032.61 lacs for quarter ending on 30-SEP-2009 against Rs. 55971.93 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 8088.51 lacs for the quarter ending on 30-SEP-2009 against Rs. 11736.01 lacs for the quarter ending on 30-SEP-2008.29 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 45579.4 lacs for half year ending on 30-SEP-2009 against Rs. 41982.93 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6272.18 lacs for the half year ending on 30-SEP-2009 against Rs. 12372.24 lacs for the half year ending on 30-SEP-2008.29 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 113401.36 lacs for half year ending on 30-SEP-2009 against Rs. 102054.42 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 13433.96 lacs for the half year ending on 30-SEP-2009 against Rs. 23273.69 lacs for the half year ending on 30-SEP-2008.27 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 27, 2009, titled "Glenmark Generics Europe announces the launch of its first Four Products for the UK market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Oct · Meeting
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the members of the Company held on September 25, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Board meeting
To consider and approve the Un-Audited Financial Results for the Second Quarter / Half Year ended September 30, 2009.9 Oct · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "At the meeting of the Operations Committee of Directors held on 8th October 2009, the Board has approved the conversion of 29200 stock options issued to its employees into 29200 Equity Shares pursuant to the ESOS 2003."
Sep 2009
30 Sep · Updates
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "Our Subsidiary Glenmark Generics Ltd. has today filed the Draft Red Herring Prospectus (DRHP) with SEBI for an Initial Public Offer".18 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "The Committee of Directors of Glenmark Pharmaceuticals Limited (the "Company") has at its meeting held on September 18, 2009 approved the allotment of 18,712,935 equity shares of face value of Re. 1 pursuant to the qualified institutions placement of its equity shares and authorized the Company to do such acts necessary to effect the allotment and listing of the equity shares".18 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 18, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Verapamil SR tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Sep · Meeting
Glenmark Pharmaceuticals Ltd.has submitted to the Exchange a copy of the proceedings of the Deemed Extra Ordinary General Meeting of the Company held on September 02, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Committee of Directors of Glenmark Pharmaceuticals Ltd. (the Company) has at its meeting held on September 14, 2009 determined September 14, 2009 to be the issue closing date and Rs. 221 per Equity Share to be the issue price pursuant to the qualified institutions placement of the equity shares. The Committee has also approved the Placement Document in respect of the equity shares proposed to be issued as aforesaid. The Company proposes to issue 18,712,935 equity shares of face value of Re. 1 each to raise aggregate proceeds of Rs. 4,135.56 million and net proceeds, after deduction of issue expenses, of Rs. 4038.19 million. The outstanding paid up capital of the Company pursuant to the issue shall be Rs. 269,581,053".11 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "The Committee of Directors of Glenmark Pharmaceuticals Limited (the "Company") has at its meeting held on September 10, 2009, pursuant to the authorization given by the shareholders given under Section 81(1A) and other applicable provisions of the Companies Act, 1956, decided to make an issuance of equity shares of face value of Re.1 each of the Company to Qualified Institutional Buyers and for this purpose, to open the issue. The Committee has also approved the Preliminary Placement Document in respect of the equity shares proposed to be issued as aforesaid".3 Sep · Meeting
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of Notice of the Annual General Meeting of the Members of the Company to be held on September 25, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Sep · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Operations Committee Meeting held today i.e. on September 3, 2009 allotted 1,98,560 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003".2 Sep · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated September 02, 2009 that "Pursuant to the notice dated July 27, 2009, the shareholders of Glenmark Pharmaceuticals Ltd have approved through postal ballot the Special Resolution at the deemed Extraordinary General Meeting (EGM) held today". A copy of the results of postal ballot shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain closed from September 14, 2009 to September 25, 2009 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on September 25, 2009 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting is payable.
Aug 2009
20 Aug · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the meeting of the Board of Directors held on August 14, 2009, Mr. D. R. Mehta has been appointed as Additional Director of the Company. Mr. D. R. Mehta is a Graduate in Arts & Law from the Rajasthan University. He also studied at Royal Institute of Public Administration, London U.K and Alfred Sloan School of Management, MIT, Boston, USA. Mr. Mehta has been a civil servant for almost four decades and has extensive and diverse experience of administration and management of public affairs. He joined the Indian Administrative Service in 1961 and has held numerous important positions in the Government of Rajasthan and later in the Government of India. He has served as the Deputy Governor of the Reserve Bank of India and as the Chairman of the Securities and Exchange Board of India. Further, at the same meeting, Mrs. B. F. Saldanha has also been appointed as Additional Director of the Company.19 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 19, 2009, titled "Forest/Glenmark announces Phase IIb Study Results for Oglemilast in Chronic Obstructive Pulmonary Disease". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 18, 2009, titled "Glenmark Confirms Patent Challenge on Atovaquone & Proguanil Hydrochloride tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.